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Summary 
Experiments were designed to study the effect of systemically administered IL-5 on local eosin- 
ophil accumulation i duced by the intradermal injection of the chemokine otaxin in the 
guinea pig. Intravenous interleukin-5 (IL-5) stimulated a rapid and dramatic increase in the 
numbers of accumulating eosinophils induced by i.d.-injected eotaxin and, for comparison, 
leukotriene B4. The numbers of locally accumulating eosinophils correlated irectly with a 
rapid increase in circulating eosinophils: circulating eosinophil numbers were 13-fold higher 1 h 
after intravenous IL-5 (18.3 pmol/kg). This increase in circulating cells corresponded with a 
reduction in the number of displaceable osinophils recovered after flushing out the femur 
bone marrow cavity. Intradermal IL-5, at the doses tested, did not induce significant eosinophil 
accumulation. We propose that these experiments simulate important early features of the tis- 
sue response to local allergen exposure in a sensitized individual, with eosinophil chemoattrac- 
tant chemokines having an important local role in eosinophil recruitment from blood mi- 
crovessels, and IL-5 facilitating this process by acting remotely as a hormone to stimulate the 
release into the circulation of a rapidly mobilizable pool of bone marrow eosinophils. This ac- 
tion of IL-5 would be complementary to the other established activities of IL-5 that operate 
over a longer time course. 
I L-5 was first described as a factor that induces differenti- .ation and prohferation of bone marrow eosinophils (1- 
3). Subsequently, IL-5 has been shown to have several 
other properties, including the ability to activate or prime 
eosinophils (4-6) and to prolong their survival in vitro (7). 
IL-5 has also been implicated in local eosinophil recruit- 
ment into tissues during allergic inflammatory reactions, 
such as those induced by helminths (8). IL-5 mR.NA ex- 
pression is upregulated in a number of tissues during eosi- 
nophilic inflammatory eactions, including those in the air- 
ways (9-11), skin (12), bladder (13), intestinal mucosa (13), 
and heart (14). IL-5 message can be upregulated in eosino- 
phils themselves, e.g., in the asthmatic lung (15). Further- 
more, IL-5 protein has been detected in bronchoalveolar 
lavage (BAL) fluid from allergen-challenged/sensitized mice 
by ELISA (16), and several studies have shown that neutral- 
izing antibodies to IL-5 suppress eosinophil accumulation 
and hyperreactivity in the lungs of experimental nimals 
during allergic inflammation (17-20). Consistent with 
these observations, intratracheal dministration of IL-5 has 
been shown to induce eosinophil accumulation in the 
guinea pig lung in vivo (21) and to induce chemotaxis of 
eosinophils in Boyden chambers in vitro (4, 6, 22, 23). 
Hence, IL-5 has been described as a selective osinophil 
chemotactic factor (4, 23). 
Against this background, we purified eosinophil chemo- 
attractant activity from the BAL fluid of challenged/sensi- 
tized guinea pigs using three sequential HPLC steps and the 
accumulation of mIn-eosinophils in guinea pig skin as the 
in vivo bioassay. No chemoattractant c ivity correspond- 
ing to IL-5 was detected in these experiments. A potent 
and selective osinophil chemoattractant ca ionic protein of 
,'o8 kD was isolated, however. This protein induced the 
rapid accumulation of mIn-eosinophils in the skin (sub- 
stantial accumulation seen within 30 rain ofintradermal in- 
jection [24]), but did not induce significant accumulation 
of ~In-neutrophils. Microsequencing of the chemoattrac- 
tant revealed a novel 73-amino acid C-C chemokine that 
we termed "eotaxin" (24, 25). Eotaxin has been cloned, 
and increased mRNA expression has been demonstrated in 
the lungs of sensitized guinea pigs after allergen challenge 
in vivo (26). 
These results are apparently at odds with the notion that 
IL-5 is an important eosinophfl chemoattractant i  vivo. 
Paradoxically, however, other studies have clearly demon- 
strated that anti-IL-5 antibodies uppress eosinophil accu- 
mulation in the same model, as discussed above. 
In this paper, we report results obtained from experi- 
ments on eosinophil accumulation i the skin, which show 
marked synergism between locally administered eotaxin 
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and systemic IL-5 and thus provide a possible explanation 
for this paradox. 
Mater ia l s  and  Methods  
Animals. Male Dunkin Hartley guinea pigs (250-300 g) pur- 
chased from Harlan Olac Ltd. (Bicester, UK) were used in all skin 
assay experiments. Female Dunkin Hartley ex-breeder guinea pigs 
(600-800 g) from the same company were used as eosinophil do- 
nors for preparation ofeosinophil peroxidase (EPO) standards. 
Materials. Human rlL-5 was purchased from tL & D Systems 
Ltd. (Oxford, UK). Leukotriene B4 (LTB4) was purchased from 
Cascade Biochem Ltd. (Reading, UK). Guinea pig eotaxin (na- 
tive protein) was prepared from the BAL fluid of allergen-chal- 
lenged animals as described previously (24). All other reagents 
and chemicals were purchased from Sigma Chemical Co. (Poole, 
UK). 
Bioassay of Eosinophil Accumulation i  Guinea Pig Skin. Guinea 
pigs were sedated (Hypnorm: fentanyl citrate/fluanisone; Janssen 
Pharmaceutical Ltd., Oxford, UK), 0.8 ml/kg intramuscularly 
and, after collection of a heparinized (10 U/ml) blood sample 
(100 p J) from the ear vein, IL-5 (18.3 pmol/kg) or PBS vehicle 
(500 ~I o f l0  mM PBS, pH 7.4, containing 0.1% low, <0.1 ng/ 
mg, endotoxin BSA) was administered intravenously. After 1 h, a 
second blood sample was obtained and test agents (eotaxin, LTB4, 
or IL-5 in HBSS/0.1% BSA, pH 7.4) were injected intradermally 
into the shaved orsal skin of the animals in duplicate sites (50 ~1 
per site). 2 h after the intradermal injections, a final blood sample 
was collected and the animals were killed by anesthetic overdose. 
The dorsal skin was removed and individual skin sites (11 mm in 
diameter) were excised and frozen at -80~ Total and differen- 
tial circulating leukocyte numbers were determined in Kimura- 
stained preparations after red blood cell lysis using Immuno-Lyse 
reagent (Coulter Electronics Ltd., Luton, UK). 
Bone Marrow Eosinophil Release Experiments. In separate ex- 
periments, the kinetics of onset of blood eosinophilia induced by 
intravenous IL-5 was studied. Furthermore, the potential role of 
the bone marrow as a source of these additional cells was investi- 
gated. Blood samples were collected before as well as 5, 15, 30, 
and 60 min after intravenous injection of IL-5 or PBS for total 
and differential leukocyte counts as described above. At the 1-h 
time point, the left femur was isolated, the femoral head and 
condyles were removed, and the displaceable c lls were recovered 
by flushing the marrow cavity of the femur shaft with 25 ml 
HBSS containing 30 mM Hepes, 0.1% BSA, and 10 mM EDTA. 
After centrifugation (250 g, 10 min, 20~ the cell pellet was re- 
suspended in 1 ml of the HBSS buffer. Total nucleated cells and 
the number of eosinophils were determined in Kimura-stained 
preparations. 
Preparation of Skin Homogenate for Measurement of EPO Activity. 
Skin samples were extracted for EPO using a modification of the 
method described by Pettipher et al. (27). Frozen skin sites were 
chopped uring thawing, and after addition of 4 ml PBS contain- 
ing 0.5% hexadecyltrimethylammonium bro ide (HTAB), sam- 
ples were homogenized (Ultra-turrax T25; Janke and KunKel 
GmbH and Co., Staufen, Germany, 3 X 15 s), sonicated (Soniprep 
150; MSE Scientific Instruments, Crawley, UK, 10 s), and frozen 
at -80~ On the day of EPO measurement, homogenate was 
thawed and centrifuged twice (2,800 g, 10 min, 20~ and 13,000 
g, 20 rain, 20~ The recovered supematant was then incubated 
at 60~ for 2 h before a final centrifugation step (13,000 g, 10 
rain, 20~ to produce sample supernatant suitable for measure- 
ment of EPO. 
Measurement of EPO in Skin Homogenate. EPO was measured 
using a modification of the method escribed by Strath et al. (28). 
Processed skin homogenate was placed in duplicate wells (100 Ixl 
per well) in a 96-well plate followed by addition of 100 Ixl sub- 
strate (8.6 mM 0-phenylenediamine dihydrochloride and 2.9 mM 
hydrogen peroxide in 0.1 M Tris/HC1, pH 8.0). After 30 rain at 
room temperature, the reaction was stopped by the addition of 50 
txl 4 M sulphuric acid and the absorbance r ad at 492 nm. 
Guinea pig EPO standard was prepared using eosinophils re- 
covered from the peritoneal cavity of donor animals given re- 
peated intraperitoneal injections of horse serum and purified 
(>98.5%) over Percoll gradients as described previously (29). Af- 
ter red blood cell lysis (resuspension in 0.2% NaC1 for 20 s, then 
addition of an equal volume of 1.6% NaC1), aliquots of eosino- 
phils (106 cells per ml PBS/0.5% HTAB) were frozen at -80~ 
Thawed aliquots were sonicated (10 s), incubated at 60~ for 2 h, 
centrifuged (13,000 g, 20 min, 20~ and the supernatant was 
used to construct an EPO calibration curve (80-10,000 cells per 
well). The cross-reactivity with guinea pig neutrophil myeloper- 
oxidase was <1% using this assay. The equivalent number of 
eosinophils per skin site was calculated from the standard curve. 
EPO standards and skin homogenates were diluted in PBS/0.5% 
HTAB, pH 7.4. 
Statistical Analysis. Statistical analysis of circulating eosino- 
phil numbers within animals and between control and treatment 
groups was determined on untransformed data using repeated 
measures analysis of variance followed by the Tukey-Kramer 
multiple comparisons test. Statistical analysis of skin responses and 
bone marrow eosinophil numbers was carried out on logl0-trans- 
formed data using an unpaired two-tail Student's t test as indi- 
cated in the figure legends. P <0.05 was considered to be statisti- 
cally significant. 
Resu l ts  
Effect of Intravenous IL-5 on the Local Accumulation of 
Eosinophils Induced by Intradermal Eotaxin and L TB 4. Exper- 
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Figure 1. The effect of intravenous IL-5 on the local accumulation of
eosinophils in response to intradermal eotaxin and LTB 4. Eosinophil ac- 
cumulation over 2 h induced by intradermal eotaxin and LTB4 (50 p,1 per 
site) 1 h after intravenous administration f IL-5 or vehicle (PBS/0.1% 
BSA). Results represent the number ofeosinophils per skin site +- SEM (n 
= 6). A significant difference between test and control groups is indicated 
by *(P <0.05). 
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iments were aimed at investigating the effect ofsystemicaUy 
administered IL-5 on local eosinophil  accumulat ion in- 
duced by intradermally injected eotaxin and, for compari -  
son, LTB 4. Prel iminary experiments suggested that intrave- 
nous IL-5 had a remarkably rapid enhancing effect on 
eosinophil  accumulat ion in the skin. The study was there- 
fore designed to address specifically the acute effects o f  in- 
travenous IL-5. IL-5 (18.3 pmol /kg)  or vehicle was in- 
jected intravenously into six pairs o f  guinea pigs. 1 h later, 
eotaxin and LTB 4 were injected intradermally and eosino- 
phil accumulat ion was measured after an additional 2 h. 
Intradermal inject ion o f  either eotaxin (0.31-1.95 pmol  
per site) or LTB4 (16-100 pmol  per site) induced a small 
dose-related eosinophil  accumulat ion in the control  group 
o f  animals, which was significant (P <0.05)  at the highest 
dose o f  eotaxin and the two higher doses o f  LTB4 (Fig. 1, 
open symbols). In animals injected intravenously with IL-5, 
the eosinophi l  accumulat ion in response to eotaxin and 
LTB 4 (Fig. 1, filled symbols) was dramatically increased at 
all the doses tested, except the lowest dose o f  eotaxin, 
when compared with the control  group. Under  these con-  
ditions, eotaxin was ~30 times more potent than LTB 4 as 
an eosinophil  chemoattractant. 
Effect of lntradermally Injected IL-5. IL-5 or vehicle was 
injected intravenously into another four pairs o f  guinea 
pigs. 1 h later, IL-5 (0.32-2.90 pmol/s ite) was injected in- 
tradermally and eosinophil  accumulat ion was determined 
after an additional 2 h as before. No  significant local eosin- 
ophil accumulat ion was induced by intradermal IL-5 in ei- 
ther set o f  animals at the doses used (Fig. 2). The  positive 
control  used in these experiments was LTB4, which gave 
responses imilar to those in Fig. 1. 
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Figure 2. The effect of intravenous IL-5 on the local accumulation of 
eosinophils in response to intradetmal IL-5 and LTB 4. Eosinophil accu- 
mulation over 2 h induced by intradermal IL-5 and LTB 4 (50 p,l per site) 
1 h after intravenous administration of IL-5 or vehicle (PBS/0.1% BSA). 
Results represent the number ofeosinophils per skin site • SEM (n = 4). 
A significant difference between test and control groups is indicated by 
*(P <0.05). 
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Circulating eosinophil numbers after intravenous IL-5 (re- 
sults from the experiments shown in Fig. 1). Circulating eosinophil num- 
ben over 3 h after intravenous administration oflL-5 or PBS/0.1% BSA. 
Results represent the number of eosinophils per milliliter of blood + 
SEM (n = 6). A significant difference between circulating levels pre- and 
postintravenous treatment within a group is indicated by # (P <0.05), 
and at a given time point between groups by *(P <0.05). Similar results 
were obtained in the group of animals used to investigate the eosinophil 
accumulation i duced by i.d. IL-5 (Fig. 2), i.e., intravenous IL-5 (n = 4) 
induced a significant increase in circulating eosinophils after 1 h (17.3 + 
6.3 • 104 cells per ml; P <0.05), but not at 3 h (9.9 --- 0.9 • 104 cells per 
ml) when compared with the preinjection level (0 h; 1.0 + 0.6 • 104 
cells per ml). In the vehicle-injected controls (n = 4), the number of cir- 
culating eosinophils did not change significantly during the 3-h period 
(i.e., 0-h level; 4.5 --- 2.7 X 104 cells per ml, 1-h level; 7.5 + 3.6 • 104 
cells per ml, 3-h level; 11.9 --- 2.4 • 10 4 cells per ml). 
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Figure 4. The kinetics of the onset of blood eosinophilia induced by 
intravenous IL-5 and the associated changes in the bone marrow pool of 
eosinophils. (a) Circulating eosinophil numbers over 1 h after intravenous 
IL-5 or PBS/0.1% BSA. Results represent the number of eosinophils per 
ml blood + SEM (n = 4). A significant difference between circulating 
levels pre- and postintravenous treatment within a group is indicated by 
# (P <0.05), and at a given time point between groups by *(P <0.05). 
(b) Femur bone marrow eosinophil numbers displaced by flushing 1 h af- 
ter intravenous IL-5 or PBS/0.1% BSA. Results represent the number of 
bone marrow eosinophils + SEM (n = 6). The total number of nucle- 
ated cells recovered from the femurs in the IL-5 and PBS groups was 6.4 
• 0.5 X 107 cells and 7.1 + 0.8 • 107 cells, respectively. A significant 
difference isindicated by **(P <0.01). In these xperiments, the circulat- 
ing eosinophil numbers were: pre-IL-5, 8.1 + 4.2 • 104 and 1 h post- 
IL-5, 28.8 + 7.2 • 104; pre-PBS, 8.4 + 3.3 • 104 and 1 h post-PBS, 3 
+ 0.4 X 104. 
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Figure 5. The relationship between cir- 
culating eosinophil numbers and the local 
accumulation f eosinophils nduced by eo- 
taxin and LTB 4. Regression analysis of cir- 
culating eosinophils atthe time of intrader- 
real injection ofeotaxin (1.95 pmol per site) 
or LTB 4 (100 pmol per site) and the local 
accumulation of eosinophils induced by 
these agonists over 2 h (results from the ex- 
periments shown in Fig. 1). Each point rep- 
resents the determination from a separate 
animal, those receiving intravenous IL-5 (n 
= 6) being indicated by the closed symbols 
and those receiving intravenous vehicle (n 
= 6) by the open symbols. The solid lines 
show linear egression, and the Spearman rank correlation coefficients (r~) are also indicated. A linear egression with a significant r~ was also seen with the 
two lower doses of each agonist, i.e., eotaxin: 0.78 and 0.31 pmol per site giving rs = 0.902 (P <0.0001) and r s = 0.769 (P <0.004), respectively; LTB4: 
40 and 16 pmol per site giving rS = 0.895 (P <0.0001) and r 5 = 0.706 (P <0.02), respectively. 
The Effect of Intravenous 11.-5 on Circulating Eosinophil 
Numbers. In the experiments described above, blood sam- 
ples were taken before intravenous injections, as well as 1 
and 3 h thereafter, i.e., at the beginning and end of the 
measurement period of  local cell accumulation. Blood eosin- 
ophil counts from the experiments using intradermal eo- 
taxin (Fig. 1) are shown in Fig. 3. Intravenous IL-5 in- 
duced a remarkably rapid effect on circulating eosinophils, 
as reported in a preliminary study (30). Intravenous IL-5 
(18.3 pmol/kg) induced a 13-fold increase in the numbers 
of  circulating eosinophils at 1 h, when compared with pre- 
injection levels (Fig. 3). Variability between animals was 
marked. Circulating eosinophil numbers also rose in vehi- 
cle-injected control animals, possibly because of handling 
or anesthesia; this increase was slow, with numbers ignifi- 
cantly above preinjection levels at 3 h. The difference be- 
tween circulating eosinophll numbers in animals injected 
intravenously with [L-5 or vehicle was significant at 1 h, 
but not at 3 h. A similar effect on circulating eosinophil 
numbers induced by intravenous IL-5 was observed in the 
second group of animals shown in Fig. 2. (see Fig. 3 leg- 
end). 
A further set of experiments were designed to investigate 
the time of onset of  blood eosinophilia induced by intrave- 
nous IL-5; these results are shown in Fig. 4 a. The signifi- 
cant increase in blood eosinophils observed 1 h after intra- 
venous IL-5 was associated with a significant decrease in 
the number of  displaceable osinophils recovered from the 
shaft of  the femur after a 25-ml flush of  the marrow cavity 
(Fig. 4 b). 
Analysis of  the data on eosinophil accumulation in the 
skin revealed a significant direct correlation between eosin- 
ophll accumulation i  response to a given dose of  eotaxin 
or LTB 4 and the number of  circulating eosinophils at 1 h 
after intravenous injection of  IL-5 or vehicle, as shown in 
Fig. 5. This was significant for all three doses of  the chemo- 
attractants used (see Fig. 5 legend). 
Discuss ion  
This study on the accumulation of  eosinophils in guinea 
pig skin demonstrates that IL-5, at the doses tested, has lit- 
tle chemoattractant activity in this in vivo system. A low 
dose of  IL-5 administered intravenously, however, has a 
rapid and dramatic enhancing effect on eosinophil accumu- 
lation induced by intradermaUy injected eotaxin. The same 
effect was also observed with intradermal LTB4, which at 
lower potency, also induces eosinophil accumulation i this 
species (29). 
These observations can provide an explanation for the 
results of  previous studies, demonstrating that acutely ad- 
ministered neutralizing antibodies to IL-5 suppress eosino- 
phil accumulation i allergen-challenged/sensitized animals 
in vivo. Our results, however, do not support he inference 
that IL-5 is an important eosinophil chemoattractant in 
vivo. It should be noted that previous tudies howing a di- 
rect chemoattractant activity of  IL-5 required high doses in 
vivo (21) and high concentrations in vitro (6). Higher in- 
tradermal doses of lL-5 were not used in our study to avoid 
the complications imposed by a proportion of  the cytokine 
gaining access to the circulation. 
The numbers of  eosinophils accumulating in response to 
intradermal eotaxin correlated with an increase in circulat- 
ing eosinophil numbers induced by intravenous IL-5. The 
blood eosinophilia induced by intravenous IL-5 was re- 
markably rapid in onset. This eosinophilia correlated with a 
significant decrease in the number of  displaceable osino- 
phils recovered from the shaft of  the femur, suggesting the 
presence of a rapidly mobilizable bone marrow pool of  
eosinophils. Further support for this is provided by the ob- 
servation that the blood eosinophilia seen 1 h after IL-5 ad- 
ministered intravenously through the ear was substantially 
reduced by previous occlusion of  the blood supply to the 
hind limbs (A. Das, S.M. Rankin, P.D. Collins, and T. J. 
Williams, unpublished observations). The cells released 
from the bone marrow by IL-5 may be at different stages of  
maturity; there are no available markers to distinguish these 
in the guinea pig. The cells appearing in the blood, how- 
ever, are clearly able to migrate rapidly into tissues. The 
presence ofa mobilizable pool of  bone marrow eosinophils 
has been suggested previously (31, 32). In these studies, 
however, the release of  the cells was demonstrated 1-2 d 
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after antigen challenge of sensitized guinea pigs. Our results 
indicate that this pool of  eosinophils may in fact be avail- 
able within a very short time (<1 h) after appropriate stim- 
ulation. In addition to releasing cells from the bone mar- 
row, IL-5 may contribute to local eosinophil accumulation 
by further mechanisms, e.g., eosinophil priming and/or fa- 
cilitating their migration through the microvascular endot- 
helium, as suggested in other studies (4, 6, 33-35). 
Taking all these observations together, we postulate the 
following sequence of events. Eotaxin expression is ob- 
served in naive guinea pig tissues (26) and may, therefore, 
be involved in a slow recruitment of  eosinophils to main- 
tain the tissue cell numbers under basal conditions. On ex- 
posure of  a tissue to allergen in a sensitized animal, there is 
an upregulation of  eotaxin mRNA (26) and an early ap- 
pearance of  protein (24). Eotaxin will be unable to induce 
recruitment to any great extent, however, if circulating cell 
numbers are low. IL-5 is also secreted locally in the tissue, 
but we propose that its initial role is hormonal, i.e., it cir- 
culates in the blood and stimulates the release of  a rapidly 
mobilizable pool of  bone marrow eosinophils. The syner- 
gism between remotely acting IL-5 and locally acting eo- 
taxin will then induce a rapid recruitment of  eosinophils in 
the allergen-stimulated tissue. In the longer term, the ef- 
fect of  IL-5 on eosinophiI differentiation and proliferation 
would manifest itsetfin an increased pool o f  available osin- 
ophils in the bone marrow and increased circulating cell 
numbers. Furthermore, together with other factors, IL-5 
can enhance eosinophil survival (22) and responsiveness 
(20) once the cells have accumulated in the allergen-stimu- 
lated tissue. 
We believe that these experiments, howing cooperation 
between a chernokine and IL-5, simulate important early 
events in the acute allergic reaction, which ensures a rapid 
accumulation of  eosinophils in tissues exposed to allergen 
in the sensitized individual. 
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